{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:24:53Z","timestamp":1783797893766,"version":"3.55.0"},"reference-count":81,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["1 U54 GM115458"],"award-info":[{"award-number":["1 U54 GM115458"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Acute myeloid leukemia (AML) is a heterogeneous disease marked by the presence of several driver mutations and molecular subgroups even in a single patient. The genetic and molecular heterogeneity is also reflected by a progressive shift from a morphologic classification to one informed by causative genomic changes. Cytogenetic results and somatic mutations are increasingly being utilized to guide use of intensive chemotherapy and low\u2010intensity chemotherapy, particularly among older adults. Utilization of next\u2010generation sequencing in AML has led to increasing use of targeted treatments for actionable mutations. Quantitative real\u2010time polymerase chain reaction\u2010based mutational analysis and multicolor flow cytometry offer sensitive assays that can detect minimal residual disease (MRD). Several studies have shown that MRD negativity, as defined by specified cutoff values, is highly prognostic with potential therapeutic implications. The last 3\u00a0years mark an unprecedented history in the drug development in AML with approval of 8 new drugs and large portfolio of ongoing early and late\u2010phase trials of several promising drugs. Multiple combinatorial trials of approved agents and approval of newer agents in the future will continue to change the therapeutic landscape of AML.<\/jats:p>","DOI":"10.1002\/cpt.1962","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T08:57:10Z","timestamp":1592902630000},"page":"506-514","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel Treatment Paradigms in Acute Myeloid Leukemia"],"prefix":"10.1111","volume":"108","author":[{"given":"Nabin","family":"Khanal","sequence":"first","affiliation":[{"name":"Franciscan Physician Network Oncology &amp; Hematology Specialists St. Francis Hospital Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristi","family":"Upadhyay Banskota","sequence":"additional","affiliation":[{"name":"Cook County Health Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Division of Hematology\u2010Oncology University of Nebraska Medical Center Omaha Nebraska USA"},{"name":"Fred and Pamela Buffett Cancer Center University of Nebraska Medical Center Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"e_1_2_18_1_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_2_18_2_1","unstructured":"Cancer stat facts: leukemia \u2010 acute myeloid leukemia (AML)<https:\/\/seercancergov\/statfacts\/html\/amylhtml>. Accessed March 19 2019."},{"key":"e_1_2_18_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00948.x"},{"key":"e_1_2_18_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_18_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22496"},{"key":"e_1_2_18_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_18_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.1034"},{"key":"e_1_2_18_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.09.028"},{"key":"e_1_2_18_9_1","first-page":"109","article-title":"Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia","volume":"16","author":"Rowley J.D.","year":"1973","journal-title":"Ann. Genet."},{"key":"e_1_2_18_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_18_11_1","first-page":"485","article-title":"Cytosine arabinoside (NSC\u201063878) and daunorubicin (NSC\u201083142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates J.W.","year":"1973","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_2_18_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.12.1583"},{"key":"e_1_2_18_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.813"},{"key":"e_1_2_18_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311402"},{"key":"e_1_2_18_15_1","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross P.F.","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_18_16_1","unstructured":"US Food and Drug Administration.Mylotarg (gemtuzumab ozogamicin for injection)<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/021174s020lbl.pdf>."},{"key":"e_1_2_18_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_2_18_18_1","unstructured":"US Food and Drug Administration (FDA).FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting BLA 761060 Mylotarg (gemtuzumab ozogamicin) 2017 <https:\/\/wwwfdagov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM566013pdf>. Accessed February 1 2020."},{"key":"e_1_2_18_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"e_1_2_18_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"e_1_2_18_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_18_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2964"},{"key":"e_1_2_18_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"e_1_2_18_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_2_18_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_2_18_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01600"},{"key":"e_1_2_18_27_1","first-page":"181","article-title":"Venetoclax (Ven) with Azacitidine (Aza) for untreated elderly acute myeloid leukemia (AML) patients (Pts) unfit for induction chemotherapy: single center clinical experience and mechanistic insights from correlative studies","volume":"130","author":"Pollyea D.A.V.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_18_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9"},{"key":"e_1_2_18_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_2_18_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869453"},{"key":"e_1_2_18_31_1","first-page":"3814","article-title":"Concomitant use of midostaurin with strong CYP3A4 inhibitors: an analysis from the ratify trial","volume":"130","author":"Ouatas T.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_18_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_2_18_33_1","unstructured":"US Food and Drug Administration (FDA).Xospata prescribing information<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211349s001lbl.pdf>. Accessed February 9 2020."},{"key":"e_1_2_18_34_1","first-page":"78","article-title":"Efficacy and safety of single\u2010agent quizartinib (Q), potent and seleefficacy and safety of single\u2010agent quizartinib (Q), a potent and selective FLT3 inhibitor (FLT3i), in patients (pts) with FLT3\u2010internal tandem duplication (FLT3\u2010ITD)\u2010mutated relapsed\/refractory (R\/R) acute myeloid leukemia (AML) enrolled in the global, phase 3, randomized controlled QuANTUM\u2010R trial","volume":"185","author":"Cortes J.E.","year":"2019","journal-title":"Br. J. Haematol."},{"key":"e_1_2_18_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984"},{"key":"e_1_2_18_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869008"},{"key":"e_1_2_18_37_1","unstructured":"US Food and Drug Administration (FDA).Ivosidenib FDA approval for firstline AML treatment<https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010ivosidenib\u2010first\u2010line\u2010treatment\u2010aml\u2010idh1\u2010mutation>. Accessed February 9 2020."},{"key":"e_1_2_18_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_18_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00040-7"},{"key":"e_1_2_18_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4075"},{"key":"e_1_2_18_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"e_1_2_18_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689"},{"key":"e_1_2_18_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074306"},{"key":"e_1_2_18_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0081-z"},{"key":"e_1_2_18_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7028"},{"key":"e_1_2_18_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.103"},{"key":"e_1_2_18_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610543"},{"key":"e_1_2_18_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-693879"},{"key":"e_1_2_18_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.113"},{"key":"e_1_2_18_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498"},{"key":"e_1_2_18_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.302"},{"key":"e_1_2_18_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1805501"},{"key":"e_1_2_18_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30580-1"},{"key":"e_1_2_18_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3425"},{"key":"e_1_2_18_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018886960"},{"key":"e_1_2_18_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124375"},{"key":"e_1_2_18_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118494"},{"key":"e_1_2_18_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0623-z"},{"key":"e_1_2_18_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.04.001"},{"key":"e_1_2_18_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.11.005"},{"key":"e_1_2_18_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e24186"},{"key":"e_1_2_18_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-132405"},{"key":"e_1_2_18_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114243"},{"key":"e_1_2_18_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.98.98"},{"key":"e_1_2_18_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027409"},{"key":"e_1_2_18_66_1","volume-title":"The First\u2010in\u2010Class Anti\u2010CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results.","author":"Sallman D.A.","year":"2019"},{"key":"e_1_2_18_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119990"},{"key":"e_1_2_18_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7042"},{"key":"e_1_2_18_69_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774"},{"key":"e_1_2_18_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.4141.4141"},{"key":"e_1_2_18_71_1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V130.Suppl_1.813.813","article-title":"Preliminary results from a phase Ib study evaluating BCL\u20102 inhibitor venetoclax in combination with MEK inhibitor cobimetinib or MDM2 inhibitor idasanutlin in patients with relapsed or refractory (R\/R) AML","volume":"130","author":"Daver N.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_18_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7063"},{"key":"e_1_2_18_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3795.3795"},{"key":"e_1_2_18_74_1","first-page":"1359","article-title":"Treating relapsed\/refractory (RR) AML with biodegradable anti\u2010CD123 CAR modified T cells","volume":"130","author":"Cummins K.D.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_18_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0547"},{"key":"e_1_2_18_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7508"},{"key":"e_1_2_18_77_1","doi-asserted-by":"crossref","unstructured":"Ravandi F.et al.Complete Responses in Relapsed\/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045 a CD123 x CD3 T Cell\u2010Engaging Bispecific Antibody: Initial Results of a Phase 1 Study.Blood(2018)132(Supplement 1):763.https:\/\/doi.org\/10.1182\/blood\u20102018\u201099\u2010119786.","DOI":"10.1182\/blood-2018-99-119786"},{"key":"e_1_2_18_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122073"},{"key":"e_1_2_18_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30576-4"},{"key":"e_1_2_18_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7011"},{"key":"e_1_2_18_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114286"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:37:56Z","timestamp":1699364276000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/cpt.1962"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1962","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"2020-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}